Crucell Signs Commercial License Agreement with SingVax for Vaccines against Japanese Encephalitis
24-Mar-2005
Crucell will receive upfront, annual and milestone payments under the agreement, as well as royalties on product sales. In addition, Crucell will have a preferred position to negotiate marketing rights outside the Asia Pacific Region with respect to a traveller's vaccine that may be developed under the agreement in case SingVax make such a product available for licensing. Further details of the agreement were not disclosed.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
Last viewed contents
GlaxoSmithKline and Archemix form strategic alliance to develop aptamers to treat inflammatory diseases
Go to page
Agilent Technologies appoints new distributors for test and measurement products in Europe
Go to page
Force Pharma Distribution - Kyiv, Ukraine
Go to page
PharmaInformatic - Emden, Germany
Go to page
FRÜH VERPACKUNGSTECHNIK AG - Fehraltorf, Switzerland
Go to page
Mobious Genomics Allowed Milestone US Sequencing Patents
Go to page
Formulatrix Europe Limited - Cork, Ireland
Go to page
MagForce publishes 2013 interim report
Go to page
Thomas_J._Bouchard_Jr.
Go to page
BYETTA Approved for Expanded Use as First-Line Treatment for Type 2 Diabetes
Go to page
Abbott Commences Tender Offer for All Outstanding Shares of Facet Biotech Corporation
Go to page
Whisky fans can drink to crop research
Go to page